Open-Label Multicentre Single-Arm Phase 2 Trial of Lanreotide Autogel (LAN) in Combination with Temozolomide (TMZ) in Patients with Advanced Well/Moderately Differentiated Neuroendocrine Tumours (NETs) of Lung and Thymus: ATLANT

#1804

Introduction: In phase 3 CLARINET study, LAN 120mg every 28 days significantly prolonged progression-free survival (PFS) vs placebo in pts with well-differentiated metastatic enteropancreatic NETs, but limited data exist for somatostatin analogues in advanced lung/thymic NETs. Evidence that TMZ may be active in thoracic NETs is mainly retrospective.

Aim(s): This prospective study will investigate safety and activity of LAN–TMZ combination in progressive lung/thymic NETs.

Materials and methods: This Italian open-label phase 2 trial is of LAN 120mg with TMZ 250mg/day (over 5 consecutive days) every 28 days for 52wks (NCT02698410; EudraCT: 2014-005579-10). Accrual goal is 40 adults with unresectable locally advanced or metastatic well/moderately differentiated lung/thymic NETs and baseline RECIST-based progression ≤1yr pre-enrolment; 13 institutions are active to enrol. Results will be available by end 2019.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Ferolla P, Berruti A, Fazio N, Mazzanti P, Houchard A,

Keywords: Temozolomide, lanreotide,